Table 3 Association study of NCF1 rs201802880 and clinical characteristics of SLE and SSc (case-case analysis).

From: Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population

 

Additive model for A allele

P

Q

OR (95%CI)

SLE

onset < 20 years vs ≥ 20 years

0.0033

0.0095

1.48 (1.14–1.93)

renal disorder present vs absent

0.85

0.89

0.98 (0.80–1.20)

neurologic disorder present vs absent

0.70

0.89

1.05 (0.81–1.36)

anti-dsDNA antibody present vs absent

0.027

0.059

1.35 (1.04–1.77)

anti-Sm antibody present vs absent

0.85

0.89

1.02 (0.82–1.27)

anti-RNP antibody present vs absent

0.80

0.89

1.03 (0.81–1.31)

SSc

dcSSc vs lcSSc

0.45

0.76

0.87 (0.59–1.25)

ATA present vs absent

0.94

0.89

1.01 (0.68–1.49)

ACA present vs absent

0.63

0.89

1.09 (0.77–1.54)

ILD present vs absent

0.65

0.89

1.08 (0.77–1.52)

  1. Genotypes of rs201802880 in SLE and SSc patients with and without specific clinical characteristics were compared using logistic regression analysis under the additive model for A allele with adjustment for sex. Significant enrichment of A allele was observed among SLE patients with onset of <20 years as compared with onset of ≥20 years. FDR P values (Q) were calculated by Benjamini-Hochberg method
  2. dcSSc: diffuse cutaneous SSc, lcSSc: limited cutaneous SSc, ATA: anti-topoisomerase I antibody, ACA: anti-centromere antibody, ILD: interstitial lung disease. Q: FDR P value.
Back to article page